Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma

被引:33
|
作者
Anand, Namrata [1 ]
Peh, Keng Hee [1 ]
Kolesar, Jill M. [1 ,2 ]
机构
[1] Univ Kentucky, Coll Pharm, Dept Pharm Practice & Sci, Lexington, KY 40508 USA
[2] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40508 USA
关键词
M1; macrophage; M2; osteosarcoma; TAM; polarization; TME; repolarization; MESENCHYMAL STEM-CELLS; TUMOR-ASSOCIATED MACROPHAGES; HIGH-GRADE OSTEOSARCOMA; TRANS-RETINOIC ACID; CHECKPOINT BLOCKADE; IMMUNE-CHECKPOINT; PD-L1; EXPRESSION; SOFT-TISSUE; OPEN-LABEL; PHASE-II;
D O I
10.3390/ijms24032858
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Macrophages are versatile immune cells and can adapt to both external stimuli and their surrounding environment. Macrophages are categorized into two major categories; M1 macrophages release pro-inflammatory cytokines and produce protective responses that lead to antimicrobial or antitumor activity. M2 or tumor-associated macrophages (TAM) release anti-inflammatory cytokines that support tumor growth, invasion capacity, and metastatic potential. Since macrophages can be re-polarized from an M2 to an M1 phenotype with a variety of strategies, this has emerged as an innovative anti-cancer approach. Osteosarcoma (OS) is a kind of bone cancer and consists of a complex niche, and immunotherapy is not very effective. Therefore, immediate attention to new strategies is required. We incorporated the recent studies that have used M2-M1 repolarization strategies in the aspect of treating OS cancer.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Early Repolarization Syndrome: Diagnostic and Therapeutic Approach
    Bourier, Felix
    Denis, Arnaud
    Cheniti, Ghassen
    Lam, Anna
    Vlachos, Konstantinos
    Takigawa, Masateru
    Kitamura, Takeshi
    Frontera, Antonio
    Duchateau, Josselin
    Pambrun, Thomas
    Klotz, Nicolas
    Derval, Nicolas
    Sacher, Frederic
    Jais, Pierre
    Haissaguerre, Michel
    Hocini, Meleze
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2018, 5
  • [42] Targeting copper to combat macrophage-driven inflammation: a potential advanced therapeutic strategy
    Weiskirchen, Ralf
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [43] Targeting copper to combat macrophage-driven inflammation: a potential advanced therapeutic strategy
    Ralf Weiskirchen
    Signal Transduction and Targeted Therapy, 8
  • [44] Targeting macrophage BTK, a potential therapeutic strategy for metabolic dysfunction-associated steatohepatitis
    Chen, Shiwei
    Zhou, Cheng
    Wang, Yanbo
    Lou, Guohua
    Zheng, Min
    JOURNAL OF HEPATOLOGY, 2024, 80 : S586 - S586
  • [45] Modulating macrophage activity via NAAA pharmacological inhibition: a therapeutic strategy for intestinal fibrosis
    Nani, M.
    De Cicco, P.
    Cattaneo, F.
    Petrosino, S.
    Tropeano, F. P.
    Miraglia, M.
    Pagano, E.
    Rinaldi, M. M.
    Izzo, A. A.
    Romano, B.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i580 - i580
  • [46] Macrophage repolarization via leptin increases immunotherapy efficacy in obesity
    Dudzinski, Stephanie O.
    Beckermann, Kathryn E.
    Young, Kirsten
    Hongo, Rachel
    Giorgio, Todd
    Rathmell, Jeffrey
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [47] Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway
    Akiyama, Toru
    Dass, Crispin R.
    Choong, Peter F. M.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (11) : 3461 - 3469
  • [48] miR-145-loaded micelleplexes as a novel therapeutic strategy to inhibit proliferation and migration of osteosarcoma cells
    Magalhaes, Mariana
    Almeida, Mauro
    Tavares-da-Silva, Elisiario
    Roleira, Fernanda M. F.
    Varela, Carla
    Jorge, Joana
    Goncalves, Ana Cristina
    Carvalho, Rui Albuquerque
    Veiga, Francisco
    Santos, Ana Claudia
    Figueiras, Ana
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 123 : 28 - 42
  • [49] Combination Therapy of Primary Tumor Resection and Immune Checkpoint Inhibitors for Metastases of Osteosarcoma: A Promising Therapeutic Strategy
    Shimizu, T.
    Fuchimoto, Y.
    Fukuda, K.
    Okita, H.
    Kitagawa, Y.
    Kuroda, T.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S345 - S345
  • [50] Fluoxetine, a Novel Therapeutic Strategy for Early Repolarization Syndrome Caused by a KCND3 Gain-of-Function Variant
    Byambajav, Tserenlkham
    Takayama, Koichiro
    Zankov, Dimitar
    Horie, Minoru
    Ohno, Seiko
    CIRCULATION, 2024, 150